BioStock: New CEO and continued patient recruitment for WntResearch

While conducting its NeoFox study, several activities are underway for cancer therapy company WntResearch to build value in the development project with Foxy-5. In its 2021 year-end report, it is clear that the company has a forward-looking focus, in particular regarding the continued patient recruitment and widening possibilities with Foxy-5. In addition, Pernilla Sandwall has been recruited as the new CEO for the company, starting at the end of April.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/02/new-ceo-and-continued-patient-recruitment-for-wntresearch/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se